Guardant Health, a leader in precision oncology, and ConcertAI, a real-world evidence (RWE) and AI technology company specializing in oncology, have announced a strategic collaboration to deliver a first-of-its-kind multi-modal real-world data (RWD) solution for biopharmaceutical companies. This partnership combines comprehensive patient electronic medical record (EMR) data with genomic and epigenomic tumor profiling, enabling deeper insights into cancer biology and treatment responses.
Cancer’s complexity arises from factors like genetic mutations, prior therapies, and drug resistance, which influence patient outcomes. The joint RWD solution offers critical clinical context by providing access to a vast database of solid tumor cancer patients with multiple liquid biopsies. This resource helps biopharma researchers better interpret disease biology, identify tumor evolution drivers, and understand resistance mechanisms to therapies.
By integrating this comprehensive dataset with the advanced analytics and AI solutions of both Guardant Health and ConcertAI, biopharmaceutical companies can gain profound insights into cancer progression and develop more effective treatments. Helmy Eltoukhy, co-CEO of Guardant Health, highlighted the significance of this collaboration: “Realizing the potential of precision medicine requires a comprehensive, multi-dimensional understanding of the tumor, the clinical environment, and the patient’s response to therapy. This partnership provides researchers with robust data and AI-based modeling, offering unprecedented insight into a patient’s cancer journey and accelerating the development of critical cancer therapies. It’s a milestone in our mission to conquer cancer with data.”
Click here to read the original news story.